Clinical Trial

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB046C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB046C monotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-14.
Status change: Not Yet Recruiting → Recruiting 2025-09-16
Trial Details
NCT Number NCT06985355
Lead Sponsor Minghui Pharmaceutical (Hangzhou) Ltd
Conditions Advanced Solid Cancer
Enrollment 200 participants
Start Date 2025-07-17
Primary Completion 2029-05 (estimated)
Study Completion 2031-05 (estimated)
Updated on ClinicalTrials.gov 2025-09-18